ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BCEL Atreca Inc

0.15
0.00 (0.00%)
Pre Market
Last Updated: 19:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 0.16
Ask Price 0.17
News -
Day High

Low
0.1023

52 Week Range

High
1.35

Day Low
Share Name Share Symbol Market Stock Type
Atreca Inc BCEL NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.15 19:00:00
Open Price Low Price High Price Close Price Previous Close
0.15
Trades Shares Traded Average Volume 52 Week Range
0 0 - 0.1023 - 1.35
Last Trade Type Quantity Price Currency
- 0 US$ 0.15 USD

Atreca Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.94M 39.62M - 0 -97.16M -2.45 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Atreca News

Date Time Source News Article
3/11/202415:12Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting..
3/11/202415:10Edgar (US Regulatory)Form 8-K - Current report
2/06/202415:00Edgar (US Regulatory)Form 8-K - Current report
1/05/202415:57Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to..
12/26/202307:39Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting..
12/26/202307:38Edgar (US Regulatory)Form 8-K - Current report
12/26/202307:30GlobeNewswire Inc.Atreca Announces Asset Purchase Agreement for Sale of..
11/14/202315:30GlobeNewswire Inc.Atreca Reports Third Quarter 2023 Financial Results and..
9/27/202318:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
9/21/202307:01Edgar (US Regulatory)Form 8-K - Current report
9/21/202307:00GlobeNewswire Inc.Atreca Announces Agreement to Terminate Lease and Departure..
9/14/202315:01Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BCEL Message Board. Create One! See More Posts on BCEL Message Board See More Message Board Posts

Historical BCEL Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.26190.28490.150.2082208621,044-0.1119-42.73%
3 Months0.12750.44480.10230.27466149,925,7090.022517.65%
6 Months0.2920.65620.10230.28094445,596,964-0.142-48.63%
1 Year1.241.350.10230.29534612,812,529-1.09-87.90%
3 Years14.9815.550.10231.651,290,389-14.83-99.00%
5 Years19.9029.350.10232.87877,489-19.75-99.25%

Atreca Description

Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture IRC technology Atreca has an unparalleled insight into how cancer patients immune responses can drive better clinical outcomes. Atreca was founded by scientists industry experts and investors who share the vision that unlocking the immune response of todays patients is the key to creating a new generation of therapies. Atreca is looking for talented entrepreneurial people who are dedicated to making a positive impact on human health.

Your Recent History

Delayed Upgrade Clock